Top

Published in:

01-10-2018 | Gastrointestinal

Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions

Authors: Edouard Reizine, Giuliana Amaddeo, Frederic Pigneur, Laurence Baranes, François Legou, Sebastien Mulé, Benhalima Zegai, Vincent Roche, Alexis Laurent, Alain Rahmouni, Julien Calderaro, Alain Luciani

Published in: European Radiology | Issue 10/2018

Abstract

Purpose

The purpose of our study was to correlate the quantitative analysis of benign hepatocellular tumor uptake on delayed hepatobiliary phase (HBP) imaging with the quantitative level of OATP expression.

Methods

This single-center retrospective study, which took place between September 2009 and March 2015, included 20 consecutive patients with a proven pathologic and immunohistochemical (IHC) diagnosis of FNH or HCA, including quantification of the OATP expression. The patients underwent Gd-BOPTA-enhancement MRI, including an HBP. The analysis of HBP uptake was performed using the liver-to-lesion contrast enhancement ratio (LLCER). Mean LLCER and OATP expressions were compared between FNH and HCA, and the expression of OATP was correlated with the LLCER value.

Results

Of the 23 benign hepatocellular tumors, 9 (39%) were FNH and 14 (61%) were HCA, including 6 inflammatory, 2 HNF1a inactivated, 3 β-catenin-mutated and 3 unclassified HCAs. On HBP, 100% of the FNH appeared hyper- or isointense, and 79% of the adenomas appeared hypointense. The mean OATP expression of FNH (46.67 ± 26.58%) was significantly higher than that of HCA (22.14 ± 30.74%) (p = 0.0273), and the mean LLCER of FNH (10.66 ± 7.403%) was significantly higher than that of HCA (-13.5 ± 12.25%) (p < 0.0001). The mean LLCER of β-catenin-mutated HCA was significantly higher than that of other HCAs (p = 0.011). Significant correlation was found between the OATP expression and LLCER values (r = 0.661; p = 0.001).

Conclusion

In benign hepatocellular tumors, the quantitative analysis of hepatobiliary contrast agent uptake on HBP is correlated with the level of OATP expression and could be used as an imaging biomarker of the molecular background of HCA and FNH.

Key Points

• Gd-BOPTA uptake on HBP correlates with the OATP level in benign hepatocellular tumors

• FNH and β-catenin-mutated HCA showed an increased lesion-to-liver contrast enhancement ratio (LLCER)

• Increased LLCER may be explained by activation of the Wnt β-catenin pathway

Cherqui D, Rahmouni A, Charlotte F et al (1995) Management of focal nodular hyperplasia and hepatocellular adenoma in young women: A series of 41 patients with clinical, radiological, and pathological correlations. Hepatology 22:1674–1681. https://doi.org/10.1016/0270-9139(95)90190-6 CrossRefPubMed

De Carlis L, Pirotta V, Rondinara GF et al (1997) Hepatic adenoma and focal nodular hyperplasia: diagnosis and criteria for treatment. Liver Transpl Surg 3:160–165CrossRef

Charny CK, Jarnagin WR, Schwartz LH et al (2001) Management of 155 patients with benign liver tumours. Br J Surg 88:808–813. https://doi.org/10.1046/j.0007-1323.2001.01771.x CrossRefPubMed

Cherqui D (2008) Clinical management of benign liver cell tumors. Gastroenterol Clin Biol 32(310-313):314. https://doi.org/10.1016/j.gcb.2008.02.012 CrossRef

Weimann A, Ringe B, Klempnauer J et al (1997) Benign liver tumors: differential diagnosis and indications for surgery. World J Surg 21:983–991CrossRef

Nault J-C, Bioulac-Sage P, Zucman-Rossi J (2013) Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology 144:888–902. https://doi.org/10.1053/j.gastro.2013.02.032 CrossRefPubMed

Nault J-C, Paradis V, Cherqui D et al (2017) Molecular classification of hepatocellular adenoma in clinical practice. J Hepatol 67:1074–1083. https://doi.org/10.1016/j.jhep.2017.07.009 CrossRefPubMed

Cadoret A, Ovejero C, Terris B et al (2002) New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene 21:8293–8301. https://doi.org/10.1038/sj.onc.1206118 CrossRefPubMed

Millet P, Moulin M, Stieger B et al (2011) How organic anions accumulate in hepatocytes lacking Mrp2: evidence in rat liver. J Pharmacol Exp Ther 336:624–632. https://doi.org/10.1124/jpet.110.175406 CrossRefPubMed

10.

Pascolo L, Cupelli F, Anelli PL et al (1999) Molecular mechanisms for the hepatic uptake of magnetic resonance imaging contrast agents. Biochem Biophys Res Commun 257:746–752. https://doi.org/10.1006/bbrc.1999.0454 CrossRefPubMed

11.

Pastor CM (2010) Gadoxetic acid-enhanced hepatobiliary phase MR imaging: cellular insight. Radiology 257:589. https://doi.org/10.1148/radiol.101172 CrossRefPubMed

12.

Planchamp C, Hadengue A, Stieger B et al (2007) Function of both sinusoidal and canalicular transporters controls the concentration of organic anions within hepatocytes. Mol Pharmacol 71:1089–1097. https://doi.org/10.1124/mol.106.030759 CrossRefPubMed

13.

Ba-Ssalamah A, Antunes C, Feier D et al (2015) Morphologic and molecular features of hepatocellular adenoma with gadoxetic acid-enhanced MR imaging. Radiology 277:104–113. https://doi.org/10.1148/radiol.2015142366 CrossRefPubMed

14.

Yoneda N, Matsui O, Kitao A et al (2016) Benign hepatocellular nodules: hepatobiliary phase of gadoxetic acid-enhanced MR imaging based on molecular background. Radiographics 36:2010–2027. https://doi.org/10.1148/rg.2016160037 CrossRefPubMed

15.

Ueno A, Masugi Y, Yamazaki K et al (2014) OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma. J Hepatol 61:1080–1087. https://doi.org/10.1016/j.jhep.2014.06.008 CrossRefPubMed

16.

Mathieu D, Rahmouni A, Anglade MC et al (1991) Focal nodular hyperplasia of the liver: assessment with contrast-enhanced TurboFLASH MR imaging. Radiology 180:25–30. https://doi.org/10.1148/radiology.180.1.2052704 CrossRefPubMed

17.

Vilgrain V, Fléjou JF, Arrivé L et al (1992) Focal nodular hyperplasia of the liver: MR imaging and pathologic correlation in 37 patients. Radiology 184:699–703. https://doi.org/10.1148/radiology.184.3.1509052 CrossRefPubMed

18.

Vilgrain V (2006) Focal nodular hyperplasia. Eur J Radiol 58:236–245. https://doi.org/10.1016/j.ejrad.2005.11.043 CrossRefPubMed

19.

Bieze M, van den Esschert JW, Nio CY et al (2012) Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: prospective study of the additional value of gadoxetate disodium. AJR Am J Roentgenol 199:26–34. https://doi.org/10.2214/AJR.11.7750 CrossRefPubMed

20.

Suh CH, Kim KW, Kim GY et al (2015) The diagnostic value of Gd-EOB-DTPA-MRI for the diagnosis of focal nodular hyperplasia: a systematic review and meta-analysis. Eur Radiol 25:950–960. https://doi.org/10.1007/s00330-014-3499-9 CrossRefPubMed

21.

Ronot M, Vilgrain V (2014) Imaging of benign hepatocellular lesions: current concepts and recent updates. Clin Res Hepatol Gastroenterol 38:681–688. https://doi.org/10.1016/j.clinre.2014.01.014 CrossRefPubMed

22.

Neri E, Bali MA, Ba-Ssalamah A et al (2016) ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Eur Radiol 26:921–931. https://doi.org/10.1007/s00330-015-3900-3 CrossRefPubMed

23.

Merkle EM, Zech CJ, Bartolozzi C et al (2016) Consensus report from the 7th international forum for liver magnetic resonance imaging. Eur Radiol 26:674–682. https://doi.org/10.1007/s00330-015-3873-2 CrossRefPubMed

24.

Kreft BP, Baba Y, Tanimoto A et al (1993) Orally administered manganese chloride: enhanced detection of hepatic tumors in rats. Radiology 186:543–548. https://doi.org/10.1148/radiology.186.2.8421762 CrossRefPubMed

25.

Ni Y, Marchal G, Yu J et al (1994) Prolonged positive contrast enhancement with Gd-EOB-DTPA in experimental liver tumors: potential value in tissue characterization. J Magn Reson Imaging 4:355–363CrossRef

26.

Ni Y, Marchal G (1998) Enhanced magnetic resonance imaging for tissue characterization of liver abnormalities with hepatobiliary contrast agents: an overview of preclinical animal experiments. Top Magn Reson Imaging 9:183–195CrossRef

27.

Grazioli L, Morana G, Kirchin MA, Schneider G (2005) Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 236:166–177. https://doi.org/10.1148/radiol.2361040338 CrossRefPubMed

28.

Grazioli L, Bondioni MP, Haradome H et al (2012) Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis. Radiology 262:520–529. https://doi.org/10.1148/radiol.11101742 CrossRefPubMed

29.

Thomeer MG, Willemssen FE, Biermann KK et al (2014) MRI features of inflammatory hepatocellular adenomas on hepatocyte phase imaging with liver-specific contrast agents. J Magn Reson Imaging 39:1259–1264. https://doi.org/10.1002/jmri.24281 CrossRefPubMed

30.

Agarwal S, Fuentes-Orrego JM, Arnason T et al (2014) Inflammatory hepatocellular adenomas can mimic focal nodular hyperplasia on gadoxetic acid-enhanced MRI. AJR Am J Roentgenol 203:W408–W414. https://doi.org/10.2214/AJR.13.12251 CrossRefPubMed

31.

Tse JR, Naini BV, Lu DSK, Raman SS (2016) Qualitative and quantitative gadoxetic acid-enhanced MR imaging helps subtype hepatocellular adenomas. Radiology 279:118–127. https://doi.org/10.1148/radiol.2015142449 CrossRefPubMed

32.

Glockner JF, Lee CU, Mounajjed T (2017) Inflammatory hepatic adenomas: characterization with hepatobiliary MRI contrast agents. Magn Reson Imaging 47:103–110. https://doi.org/10.1016/j.mri.2017.12.006 CrossRefPubMed

33.

Roux M, Pigneur F, Calderaro J et al (2015) Differentiation of focal nodular hyperplasia from hepatocellular adenoma: role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI. J Magn Reson Imaging 42:1249–1258. https://doi.org/10.1002/jmri.24897 CrossRefPubMed

34.

Cassidy FH, Yokoo T, Aganovic L et al (2009) Fatty liver disease: MR imaging techniques for the detection and quantification of liver steatosis. Radiographics 29:231–260. https://doi.org/10.1148/rg.291075123 CrossRefPubMed

35.

Fléjou J-F (2011) WHO Classification of digestive tumors: the fourth edition. Ann Pathol 31:S27–S31. https://doi.org/10.1016/j.annpat.2011.08.001 CrossRefPubMed

36.

Zucman-Rossi J, Jeannot E, Nhieu JTV et al (2006) Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatol Baltim Md 43:515–524. https://doi.org/10.1002/hep.21068 CrossRef

37.

Bioulac-Sage P, Laumonier H, Couchy G et al (2009) Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatol Baltim Md 50:481–489. https://doi.org/10.1002/hep.22995 CrossRef

38.

van Kessel CS, de Boer E, ten Kate FJW et al (2013) Focal nodular hyperplasia: hepatobiliary enhancement patterns on gadoxetic-acid contrast-enhanced MRI. Abdom Imaging 38:490–501. https://doi.org/10.1007/s00261-012-9916-0 CrossRefPubMed

39.

van Aalten SM, Verheij J, Terkivatan T et al (2011) Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice. J Hepatol 55:120–125. https://doi.org/10.1016/j.jhep.2010.10.030 CrossRefPubMed

40.

Kitao A, Matsui O, Yoneda N et al (2015) Hepatocellular carcinoma with β-catenin mutation: imaging and pathologic characteristics. Radiology 275:708–717. https://doi.org/10.1148/radiol.14141315 CrossRefPubMed

41.

Vilgrain V, Van Beers BE, Pastor CM (2016) Insights into the diagnosis of hepatocellular carcinomas with hepatobiliary MRI. J Hepatol 64:708–716. https://doi.org/10.1016/j.jhep.2015.11.016 CrossRefPubMed

42.

Kitao A, Matsui O, Yoneda N et al (2017) Gadoxetic acid-enhanced magnetic resonance imaging reflects co-activation of β-catenin and hepatocyte nuclear factor 4α in hepatocellular carcinoma. Hepatol Res. https://doi.org/10.1111/hepr.12911 CrossRef

43.

Kanda T, Osawa M, Oba H et al (2015) High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology 275:803–809. https://doi.org/10.1148/radiol.14140364 CrossRefPubMed

44.

Kahn J, Posch H, Steffen IG et al (2017) Is there long-term signal intensity increase in the central nervous system on T1-weighted images after MR imaging with the hepatospecific contrast agent agdoxetic acid? A cross-sectional study in 91 patients. Radiology 282:708–716. https://doi.org/10.1148/radiol.2016162535 CrossRefPubMed

Title: Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions
Authors: Edouard Reizine
Giuliana Amaddeo
Frederic Pigneur
Laurence Baranes
François Legou
Sebastien Mulé
Benhalima Zegai
Vincent Roche
Alexis Laurent
Alain Rahmouni
Julien Calderaro
Alain Luciani
Publication date: 01-10-2018
Publisher: Springer Berlin Heidelberg
Published in: European Radiology / Issue 10/2018
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-018-5438-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions

Abstract

Purpose

Methods

Results

Conclusion

Key Points

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Key Points

Please log in to get access to this content

Other articles of this Issue 10/2018

Improvement of radiology reporting in a clinical cancer network: impact of an optimised multidisciplinary workflow

Frequency and characteristics of contralateral breast abnormalities following recall at screening mammography

Experience of neuroprotective air injection during radiofrequency ablation (RFA) of spinal osteoid osteoma

Accurate IVIM model-based liver lesion characterisation can be achieved with only three b-value DWI

Remote brain microhaemorrhages may predict haematoma in glioma patients treated with radiation therapy

Mesenteric lymph nodes in MR enterography: are they reliable followers of bowel in active Crohn’s disease?